Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the prevalence of fatty liver and its association with obesity and insulin resistance in patients with chronic hepatitis C
- Summarize the impact of obesity, insulin resistance, and steatosis on the natural history of chronic hepatitis C
- Discuss the outcome of insulin-based therapy in chronic hepatitis C patients with insulin resistance and/or steatosis
Topics covered include:
- Introduction
- Pathogenesis of Insulin Resistance and Steatosis and the Impact of Obesity in HCV Infection
- Chronic Hepatitis C, Insulin Resistance, and Type 2 Diabetes
- Genotype 3 HCV and the Risk of Developing Steatosis
- Oxidative Stress and Mitochondrial Dysfunction
- Liver Disease Progression in the Setting of Insulin Resistance and Hepatic Steatosis
- Effect of Insulin Resistance and Steatosis on Response to Interferon-Based Therapy
- Potential Mechanisms Underlying Reduced Virologic Clearance
- Concomitant Therapies to Improve HCV Therapy Response: Antioxidant Therapy
- Concomitant Therapies to Improve HCV Therapy Response: Modulating Lipid Metabolism and Weight Loss
- Concomitant Therapies to Improve HCV Therapy Response: Insulin-Sensitizing Agents
- Summary of Implications for Clinical Practice